A new 5-HT3 receptor ligand. II. Structure-activity analysis of 5-HT3 receptor agonist action in the gut

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 3, 1998, Pages 445-451

  Yamada, Megumi ^a   Sato, Yasuo ^a   Kobayashi, Kazuko ^a   Konno, Fukio ^a   Soneda, Tomoko ^a   Watanabe, Takashi ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

1 Allyl 1 methyl 4 (2 benzoxazolyl)piperazinium iodide (CP2289); 5 HT3 receptor; Agonist

Indexed keywords

1 (3 CHLOROPHENYL)BIGUANIDE; 1 ALLYL 1 METHYL 4 (2 BENZOXAZOLYL)PIPERAZINIUM IODIDE; 1 ALLYL 1 METHYL 4 (5 TERT BUTYLBENZOXAZOL 2 YL)PIPERAZINIUM BROMIDE; 2 PIPERAZINYLBENZOXAZOLE DERIVATIVE; CP 2289; SEROTONIN; SEROTONIN AGONIST; UNCLASSIFIED DRUG; BENZOXAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; DOSE RESPONSE; DRUG RECEPTOR BINDING; GUINEA PIG; INHIBITION KINETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PROTEIN QUATERNARY STRUCTURE; RAT; SEROTONIN RELEASE; STOMACH MOTILITY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; WISTAR RAT;

ANIMALS; BENZOXAZOLES; CRYSTALLOGRAPHY, X-RAY; MALE; MODELS, MOLECULAR; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031965830     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.445     Document Type: Article

References (23)

1. a) Part I: Sato Y., Imai M., Amano K., Iwamatsu K., Konno F., Kurata Y., Sakakibara S., Hachisu M., Izumi M., Matsuki N., Saito H., Biol. Pharm. Bull., 20, 752-755 (1997);
2. b) The 16th Symposium on Medicinal Chemistry, Program and Abstracts, pp. 143-144 (1996).
3. For reviews, see: a) Kilpatrick G. J., Bunce K. T., Med. Res. Rev., 10, 441-475 (1990); b) King F. D., Sanger G. J., Drugs of the Future, 14, 875-889 (1989).
4. For reviews, see: a) Kilpatrick G. J., Bunce K. T., Med. Res. Rev., 10, 441-475 (1990); b) King F. D., Sanger G. J., Drugs of the Future, 14, 875-889 (1989).
5. a) Gyermek L., J. Clin. Pharmacol., 35, 845-855 (1995);
6. b) Yoshioka M., Saito H., Tampakushitsu, Kakusan, Koso, 40, 700-708 (1995).
7. a) Andrews P. L. R., Blower P. R., J. Pharm. Med., 13, 153-191 (1995);
8. b) Kato M., Ito K., Nishino S., Yamakuni H., Takasugi H., Chem. Pharm. Bull., 42, 2546-2555 (1994).
9. a) Ohta M., Suzuki T., Furuya T., Kurihara H., Tokunaga T., Miyata K., Yanagisawa I., Chem. Pharm. Bull., 44, 1707-1716 (1996);
10. b) Evans S. M., Galdes A., Gall M., Pharmacol. Biochem. Behavior., 40, 1033-1040 (1991);
11. c) Hilbert M. F., Hoffman R., Miller R. C., Carr A. A., J. Med. Chem., 33, 1594-1600 (1990).
12. a) Dukat M., Abdel-Rahman A. A., Ismaiel A. E. M., Ingher S., Teitler M., Gyermek L., Glennon R. A., J. Med. Chem., 39, 4017-4026 (1996);
13. b) Rault S., Lancelot J. C., Prunier H., Robba M., Renard P., Delagrange P., Pfeifier B., Caignard D. H., Guardiola-Lemaitre B., Hammon M., ibid., 39, 2068-2080 (1996);
14. c) Clark R. D., Muchowski J. M., Weinhardt K. K., Dillon M. P., Bioorganic. Med. Chem. Lett., 5, 1853-1856 (1995);
15. d) Bermudez J., Boyland P., King F. D., Summersell R. J., ibid., 3, 205-208 (1993).
16. Dunner J., Chem. Ber., 9, 465-466 (1876).
17. a) Glennon R. A., Dukat M., "Update 1992 Curr. Drugs: Serotonin,"1992, pp. 1-45;
18. b) Dukat M., Miller K., Teitler M., Glennon R. A., Med. Chem. Res., 1, 271-276 (1991).
19. Glennon R. A., Ismaiel A. E. M., McCarthy B. G., Peroutka S. J., Eur. J. Pharmacol., 168, 387-392 (1989).
20. Newberry N. R., Cheshire S. H., Gilbert M. J., Brit. J. Pharmacol., 102, 615-620 (1991).
21. Kilpatrick G. J., Bunce K. T., Tyers M. B., Med. Res. Rev., 10, 441-475 (1990).
22. Kilpatrick G. J., Jones B. J., Tyers M. B., Nature (London), 330, 746-748 (1987).
23. Fozard J. R., Host M., Brit. J. Pharmacol., 77, 520P (1982).